Argenx Lead as Chugai's Muscle Disease Treatment DisappointsIn a whirlwind of market reactions, biotech stocks Argenx ( NASDAQ:ARGX ) and Immunovant ( NASDAQ:IMVT ) emerged as frontrunners on Thursday, propelled by disappointing results from Japanese rival Chugai Pharmaceutical. The contrast in fortunes underscores the high stakes and volatile nature of the